Paul G. Allen Frontiers Group [to 28 Sep 2019]
No new digest content identified.


BMGF – Gates Foundation [to 28 Sep 2019]
SEPTEMBER 25, 2019
Prime Minister Ardern and Prime Minister Sanchez to Join Bill and Melinda Gates at Goalkeepers 2019 in New York City
Third annual Goalkeepers event will focus on global inequality and the importance of designing health and education investments to prioritize the poorest

SEPTEMBER 25, 2019
Pakistan and the Bill & Melinda Gates Foundation Unveil Collaboration on Ehsaas Program to Alleviate Poverty
PM Khan said this is “the biggest anti-poverty project ever launched in the country and it has been planned with a great deal of attention to detail. I’m pleased that the Bill & Melinda Gates Foundation will assist with a range of activities including accelerating stunting reduction programs, supporting financial inclusion initiatives and investing in public health systems to improve health and reduce maternal, newborn and child mortality.”

SEPTEMBER 24, 2019
Goalkeepers Global Goals Awards Presented in New York on September 24
Bill and Melinda Gates, co-chairs of the Bill & Melinda Gates Foundation, co-hosted the fourth annual Goalkeepers Global Goals Awards on September 24 in New York to celebrate outstanding work around the world that is directly linked to the United Nations Sustainable Development Goals (Global Goals).
The Changemaker Award was presented to youth activist Payal Jangid for her fight against child labor and child marriage in India. The Progress Award was presented to Gregory Rockson, co-founder and CEO of mPharma, for his work to increase access to high-quality drugs across community pharmacies in five African countries. The Campaign Award was presented to Aya Chebbi, the first African Union Youth Envoy, for her work promoting youth empowerment, peacebuilding, and non-violent mobilization in Africa.
The Global Goalkeeper Award was presented to Prime Minister Narendra Modi of India for the progress India is making in improving sanitation through the Swachh Bharat mission. Before the Swachh Bharat mission, over 500 million people in India did not have access to safe sanitation, and now, the majority do.


Bill & Melinda Gates Medical Research Institute [to 28 Sep 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 28 Sep 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
09.24.2019  |
T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, and CARB-X, a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria, announced today that the T2Resistance™ Panel is the first diagnostic to graduate from CARB-X’s portfolio. The graduation marks an important milestone on the path toward approval for use on patients in hospitals in the U.S., Europe and elsewhere around the globe.


CEPI – Coalition for Epidemic Preparedness Innovations [to 28 Sep 2019]
No new digest content identified.


Clinton Health Access Initiative, Inc. (CHAI) [to 28 Sep 2019]
News & Press Releases
No new digest content identified.


EDCTP [to 28 Sep 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 28 Sep 2019]
Website not responding at inquiry


European Medicines Agency [to 28 Sep 2019]
News and press releases
No new digest content identified.


European Vaccine Initiative [to 28 Sep 2019]
Latest news
No new digest content identified.


FDA [to 28 Sep 2019]
September 27, 2019 – FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels

September 26, 2019 – FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks

September 26, 2019 – Statement on new steps to advance digital health policies that encourage innovation and enable efficient and modern regulatory oversight

September 24, 2019 – FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox
The U.S. Food and Drug Administration announced today the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease.

“Following the global Smallpox Eradication Program, the World Health Organization certified the eradication of naturally occurring smallpox disease in 1980. Routine vaccination of the American public was stopped in 1972 after the disease was eradicated in the U.S. and, as a result, a large proportion of the U.S., as well as the global population has no immunity,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Therefore, although naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect. Today’s approval reflects the U.S. government’s commitment to preparedness through support for the development of safe and effective vaccines, therapeutics, and other medical countermeasures.”

Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed…


Fondation Merieux [to 28 Sep 2019]
National Health Laboratory Project launched in Myanmar
September 27, 2019, Myanmar
French Development Agency (AFD), European Union (EU) and Ministry of Health and Sports (MoHS) to collaborate on improving Myanmar’s ability …

Launch of Phase III of a collaborative project to prevent and control tuberculosis in China
September 25, 2019, China
The Mérieux Foundation has launched Phase III of a project to improve the prevention and control of tuberculosis (TB) in …

Creation of the Alliance Pasteur Mérieux International
Two major French players in the fight against infectious diseases join forces to improve public health in vulnerable countries
September 24, 2019, Lyon (France)
[See Milestones above for more detail]


Gavi [to 28 Sep 2019]
Latest news
24 September 2019
Multilateral agencies launch a joint plan to boost global health goals
Health, development and humanitarian agencies will collaborate for greater efficiency and more streamlined support to countries to deliver universal health coverage and achieve the health-related Sustainable Development Goals targets.
[See Milestones above for more detail]

24 September 2019
Prime Minister of Bangladesh receives 2019 Vaccine Hero Award
Her Excellency Sheikh Hasina recognised for championing immunisation both nationally and globally.


GHIT Fund [to 28 Sep 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.


Global Fund [to 28 Sep 2019]
News & Stories
Tribute to Jacques Chirac, Determined Opponent of AIDS and Global Fund Partnership Trailblazer
26 September 2019

Global Fund Applauds Spain’s €100 Million Pledge
25 September 2019
NEW YORK – The Global Fund applauds the announcement by the government of Spain that it will contribute €100 million to the Global Fund over the next three years.
The pledge marks the return of Spain as a donor and demonstrates the country’s strong commitment to end the epidemics of HIV, tuberculosis and malaria and build stronger and more sustainable health systems around the world…

Multilateral Agencies Launch Joint Plan to Boost Global Health Goals
24 September 2019

Data Explorer: Country Documents
24 September 2019

Global Fund Applauds World Leaders’ Commitment to Universal Health Coverage
23 September 2019

Annie Lennox, Diane Kruger, Natalie Portman and Penélope Cruz Call on the World to End Epidemics
23 September 2019

Technical Evaluation Reference Group Thematic Review: Resilient and Sustainable Systems for Health
23 September 2019

Technical Evaluation Reference Group Thematic Review: Partnerships
23 September 2019


Hilleman Laboratories [to 28 Sep 2019]
No new digest content identified.


Human Vaccines Project [to 28 Sep 2019]
Press Releases
No new digest content identified.


IAVI [to 28 Sep 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities (ICMRA)
Statements and Press Releases
No new digest content identified.



No new digest content identified.


IFRC [to 28 Sep 2019]
Selected Press Releases, Announcements
Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua
Dengue spreads across Central America, Red Cross scales up response
Panama/Geneva, 27 September 2019 –-As dengue spreads rapidly across Central America, the International Federation of Red Cross and Red Crescent Societies (IFRC) is scaling up emergency assistance to help countries contain the mosquito borne viral disea …
27 September 2019

New “game-changing” financing mechanism to end cholera launched at UN General Assembly
New York, 26 September 2019 – The Islamic Development Bank (IsDB) and the International Federation of Red Cross and Red Crescent Societies (IFRC) today unveiled a major new initiative to combat cholera and other diarrheal diseases in 29 member countries of the Organization of Islamic Cooperation (OIC).
Announced at the UNGA Financing for Development Dialogues by H.E. The Honorable Minister of Economy, Malaysia, Mohamed Azmin, the One WASH Fund will attempt to cut cholera deaths by 90 per cent and improve the lives of 5 million people in 29 cholera affected OIC member countries.
The One WASH Fund is a scalable outcome fund model that uses an innovative financing mechanism designed to attract new philanthropic and private investor capital by combining Islamic social finance contributions with traditional humanitarian donor financing. This Fund structure will then be pre-funded through the issuance of an Islamic bond (Sukuk) enabling it to operate at multi-million-dollar scale…


IVAC [to 28 Sep 2019]
No new digest content identified.


IVI [to 28 Sep 2019]
Selected IVI News & Announcements
IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance
September 24, 2019, SEOUL, Korea – The Chief Medical Officer for England, Dame Sally Davies, announced today during the 74th UN General Assembly that a consortium led by the International Vaccine Institute (IVI) has been awarded a £2.7m Fleming Fund Regional Grant to improve data sharing and bolster global policy against antimicrobial resistance (AMR). If unchecked, by 2050, an estimated 10 million people will die annually of infections by drug resistant bacteria at a cost of $100 trillion…
“Achieving our common goal of universal health coverage will require global action on a multitude of fronts, including tackling the escalating threat of antimicrobial resistance and investing in research,” Dame Sally Davies said. “I am delighted to announce this funding, which will catalyse regional collaboration to help strengthen AMR surveillance systems across Africa and Asia.”…

The CNBG and IVI exchange MOU to provide high-quality vaccines to developing countries
September 23, 2019, SEOUL, Korea — On September 9, 2019, the China National Biotec Group (CNBG) and the International Vaccine Institute (IVI) held a meeting at the Hongqiao Office of Shanghai Institute of Biological Products (SIBP) and signed a memorandum of understanding.
CNBG’s Vice President, Dr. Yuntao Zhang, and Dr. Jerome Kim, Director General of IVI, both delivered opening speeches, expressing their wishes and expectations for the forthcoming cooperation between the two parties. During the meeting, the two parties identified specific areas of collaboration: typhoid conjugate vaccine, rotavirus vaccine and monoclonal antibody. The parties will combine forces on R&D and clinical activities on these subjects and jointly fulfill the mission of providing high-quality vaccines to developing countries. In addition, the two sides exchanged information and formulated the main objectives and work plan for the next phase…


JEE Alliance [to 28 Sep 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 28 Sep 2019]
Latest [Selected Announcements]
Access to medicines
6 things Big Pharma doesn’t want you to know!
Project Update 26 Sep 2019

DRC Ebola outbreaks
Crisis update – September 2019
Crisis Update 23 Sep 2019

DRC Ebola outbreaks
Independent Ebola vaccination committee is needed to overcome lack of WHO transparency
Press Release 23 Sep 2019
[See DRC Ebola above for more detail]


NIH [to 28 Sep 2019]
Selected News Releases
NIH awards contracts to advance tuberculosis immunology research
September 26, 2019 — Research will help advance TB vaccine development.

New NIH program provides comprehensive treatment for inherited blood and immune diseases
September 26, 2019 — Streamlined process integrates expertise from many medical specialties and related basic science disciplines.

NIH funds centers for advancing the reference sequence of the human genome
September 24, 2019 — Funding is necessary for making advances in DNA sequencing technology and computational methods possible.


PATH [to 28 Sep 2019]
Selected Announcements
Memorandum of Understanding between PATH and MURC
A collaborative effort toward creating Digital Health Ecosystems in LMICs
Seattle, Washington, USA, September 27, 2019 – We are pleased to announce that Mitsubishi UFJ Research and Consulting Co., Ltd. (Tokyo Japan, President: Satoshi Murabayashi, “MURC”) and PATH (Seattle USA, President and CEO: Steve Davis) have signed a Memorandum of Understanding (MoU) in order to collaborate in the creation of digital health ecosystems in low and middle income countries (LMICs) and innovative projects using advanced technologies, building on the capabilities, knowledge and network of both parties. Through these collaborative activities, both parties will contribute to the promotion of global health and greater health equity…


ProMED [Program for Monitoring Emerging Diseases] [to 28 Sep 2019]
International Society for Infectious Diseases
Selected Announcements/Posts
No new digest content identified.


Sabin Vaccine Institute [to 28 Sep 2019]
No new digest content identified.


UNAIDS [to 28 Sep 2019]
Selected Press Releases/Reports/Statements
27 September 2019
HIV in small island developing states

27 September 2019
The pros and cons of being small

26 September 2019
Without sustainable financing the AIDS response will fail

26 September 2019
Communities of faith―helping to find the missing men and seeking justice for children

25 September 2019
Young people taking action, inspiring change

24 September 2019
Botswana extends free HIV treatment to non-citizens
The Government of Botswana has decided to extend free HIV treatment to foreign residents in a major policy shift that closes a significant gap in the country’s response to the epidemic.
There are an estimated 30 000 foreign residents living with HIV in Botswana, but less than a quarter of them currently have access to treatment. Many foreign residents are simply unable to afford medicines or return home to seek medical help.
Botswana has the third highest HIV prevalence in the world, with more than one in five of the adult population aged 15–49 years living with the virus. In 2016, the country decided to adopt a treat all strategy by extending free treatment to all citizens living with HIV, a step that has been yielding significant results. Since 2010, AIDS-related deaths have decreased by a third, with new HIV infections down by 36% over the same period.
“I commend Botswana for extending free treatment to foreign residents living with HIV,” said Gunilla Carlsson, UNAIDS Executive Director, a.i. “This measure will save lives and help the entire country progress towards ending the AIDS epidemic―it is another example of Botswana’s leadership and its determination to leave no one behind in the response to HIV.”…

24 September 2019
Making a difference in Ethiopia one district at a time


UNICEF [to 28 Sep 2019]
Selected Statements, Press Releases, Reports
News note
Geneva Palais briefing note: 123,000 children affected by flooding in Niger
This is a summary of what was said by Marixie Mercado, UNICEF spokesperson in Geneva – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.

Press release
Sulawesi earthquake one year on: Over 1 million children and parents reached

UNICEF Executive Director, Henrietta Fore CRC @ 30 Commemoration Event

UNICEF Executive Director Henrietta Fore remarks on young people and climate change


Vaccination Acceptance Research Network (VARN) [to 28 Sep 2019]
No new digest content identified.


Vaccine Confidence Project [to 28 Sep 2019]
22 Sep, 2019
Article of the week: The World Knows an Apocalyptic Pandemic Is Coming
Another important wake-up call from Laurie Garrett — a wake-up call to wake-up. There are some issues where evidence is not the issue, where  “more research” is not needed.  The issue instead is that we  are not paying enough attention to the evidence we do have, and it is putting human lives and societies at risk. -HL
 The World Knows an Apocalyptic Pandemic Is Coming: But nobody is interested in doing anything about it. 
BY LAURIE GARRETT | Foreign Policy, SEPTEMBER 20, 2019


Vaccine Education Center – Children’s Hospital of Philadelphia [to 28 Sep 2019]
Webinar archive
The archived recording of the September 2019 webinar, Current Issues in Vaccines, presented by Dr. Paul Offit, is available for viewing on the Vaccine Update website.
Topics discussed include:
:: HPV vaccine for 27- to 45-year-olds: Routine recommendation?
:: PCV13 vaccine for older adults: Is it making a difference?
:: Influenza vaccine: A rough year
:: Meningococcal B vaccine: When do you need a booster dose?
Information related to obtaining free continuing education credits (CME, CEU or CPE) is included at the end of the recording. 


Wellcome Trust [to 28 Sep 2019]
Opinion | 25 September 2019
This can be a pivotal moment for global health by Alex Harris
What the global action plan being launched at the UN General Assembly means for research and innovation.

Opinion | 23 September 2019
Researchers pay the cost of research
Ben Bleasdale, Policy Adviser Wellcome
Excellence in research shouldn’t come at the expense of those who make it happen.


Why We Vaccinate [to 28 Sep 2019]
Why We Vaccinate Announces Coalition Formation and Board Members
New Coalition to Advocate for Vaccine Adherence and Improved Health Outcomes
September 23, 2019
WASHINGTON–(BUSINESS WIRE)–Today, Why We Vaccinate, a new not-for-profit, pro-vaccine coalition, announced its formation and founding board members. Why We Vaccinate is on a mission to advocate for pro-health legislation, improve immunization conversations between doctors and patients and respond to anti-vaccine misinformation…

“Vaccines are one of the safest, most widely-adopted health care practices in the world,” said Dr. William Hearl, board president and experienced vaccinologist. “Why We Vaccinate will spread the message that vaccines are rigorously tested and provide the best defense against diseases, like the measles, that can have a lasting impact on your child’s immune system.”
Why We Vaccinate is supported by the scientific community, academia, health organizations and pro-vaccine advocates.

The coalition is governed by a Board of Directors that includes:
Dr. William Hearl, board president, founder, Immunomic Therapeutics
Athanasia Anagnostou, board secretary, Senior Director of Corporate Development, Immunomic Therapeutics
Phyllis Arthur, board member, Vice President of Infectious Diseases & Diagnostics Policy, BIO
Dr. Michael Olin, board member, Associate Professor in the Department of Pediatrics, University of Minnesota …


The Wistar Institute [to 28 Sep 2019]
Press Release Sep. 26, 2019
Integral Molecular Announced as First Industry Partner in The Wistar Institute’s Biomedical Research Technician Apprenticeship
PHILADELPHIA – Sept. 25, 2019 – The Wistar Institute, a global leader in cancer, immunology and infectious disease research, has selected Integral Molecular, Inc. as the first industry partner for its Biomedical Research Technician (BRT) Apprenticeship. This industry-academia relationship continues Integral Molecular’s dedication to community partnership, economic development, and job creation in the city of Philadelphia.

Press Release Sep. 24, 2019
Wistar Receives More than $12 Million to Fund Innovative Clinical Research on the Impact of Opioid Use on Response to Therapy in People Living with HIV
PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program. The consortium, including several partner institutions in the U.S.


World Organisation for Animal Health (OIE) [to 28 Sep 2019]
‘United Against Rabies’ collaboration celebrates one year of progress towards zero human rabies deaths by 2030
Since the launch of ‘Zero by 30’ in 2018, the United Against Rabies collaboration has made progress to empower, engage and enable countries to reach the rabies elimination goal by 2030. Released today on World Rabies Day, the first annual progress report describes the incremental, collaborative impact of the four partners[1] in promoting the One Health approach[2] and achieving the three objectives of the Global Strategic Plan.

Facilitating access to vaccines, medicines and education
:: In addressing the first objective of the Plan: Eliminate rabies by effective use of vaccines, medicines, tools and technologies, the UAR collaboration enabled the implementation of concrete actions in countries aimed at tackling rabies at its source: infected dogs. In 2018, these efforts included:
:: Increasing access to high-quality dog rabies vaccines, by delivering more than 2 million doses to 13 countries in Asia and Africa, through the OIE Rabies Vaccine Bank;
:: Improving care for dog bite cases with potential human rabies exposure, by convening training for more than 450 health professionals in 70 of the 89 countries in which human rabies occurs, delivered by WHO and other UAR partners.
:: Enhancing rabies education and awareness through World Rabies Day webinars organized by FAO and other UAR partners, as well as almost 200 events on World Rabies Day registered on the GARC website from 62 countries, attracting significant exposure through printed, digital and social media channels. Capacity-building workshops in communications were also delivered by the OIE…





ARM [Alliance for Regenerative Medicine] [to 28 Sep 2019]
September 24, 2019
ARM and NAMCP Publish Recommendations to Increase Patient Access in Joint Study, “Roadmap for Navigating Cell and Gene Therapy Value Demonstration and Reimbursement in U.S. Managed Care”
The Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) Medical Directors Institute announced today the joint release of their recent study of medical director and manufacturer perspectives on value demonstration and reimbursement for cell- and gene-based regenerative and advanced therapies.
The study results are available to download here.


BIO [to 28 Sep 2019]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network [to 28 Sep 2019]
DCVMN 20th Annual General Meeting
21 October 2019 to 23 October 2019
Rio de Janeiro / Brazil


IFPMA [to 28 Sep 2019]
Selected Press Releases, Statements, Publications
IFPMA statement on UHC Political Declaration at UNGA74
New York, 23 September 2019: IFPMA congratulates the United Nations General Assembly in holding the first-ever high-level meeting on Universal Health Coverage (UHC) and welcomes the adoption of the Political Declaration on UHC at its 74th session.

IFPMA and its members welcome the declaration’s call to address healthcare in a holistic way and the elevation of health discussions beyond the ministries of health. We support the emphasis on “the importance of national ownership and the primary role and responsibility of governments at all levels to determine their own path towards achieving universal health coverage, in accordance with national contexts and priorities, and underscore the importance of political leadership for universal health coverage beyond the health sector in order to pursue whole-of government and whole-of-society approaches, as well as health-in-all-policies approaches, equity- based approaches and life-course approaches.”(Para 6)

UHC is a journey unique to each country’s needs and priorities, and there is no one-size-fits-all approach. Each country must deploy necessary resources to achieve them and must prioritize which health services to cover, what beneficiary population groups to cover, how to pay for those services, and how to ensure effective and efficient delivery in consultation with stakeholders.  Regardless of a country’s unique needs, no single organization or sector can achieve UHC on its own and in recognition of the need to move together towards achieving UHC, we are committed to playing our part.

As a partner of the UHC 2030 global movement, IFPMA and its members reinforce the private sector’s commitments to achieving universal health coverage and fully support the Key Asks and the Global Compact, which outlines five key principles to guide collective action towards UHC. IFPMA and its members strongly believe that an enabling environment is fundamental to UHC – one that works towards strengthening quality primary health care, investing more and better in health and improving access to affordable and quality-assured essential health products.

IFPMA firmly believes that collaborative and innovative action on UHC is needed to meet our shared goals of expanding patient access to medicines and achieving the long-term sustainability of the health sector.  Together, UHC and life sciences innovation promotes continued global health progress and well-being for all.  We remain committed to playing our part to help Member States achieve UHC and look forward to constructive and inclusive dialogue to ensure implementation.

IFPMA Response to the WHO Fair Pricing Forum survey
16 September 2019


PhRMA [to 28 Sep 2019]
Selected Press Releases, Statements
Press Release
PhRMA Statement on Speaker Pelosi’s Radical Plan
WASHINGTON, D.C. (September 19, 2019) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:
“Speaker Pelosi’s radical plan would end the current market-based system that has made the United States the global leader in developing innovative, lifesaving treatments and cures. It would fundamentally restructure how patients access medicines by giving the federal government unprecedented, sweeping authority to set medicine prices in public and private markets while importing price controls from other countries that restrict access to innovative medicines. It would upend the successful Medicare Part D program that 40 million seniors rely on without any guarantee that savings would be used to lower costs at the pharmacy counter. We do not need to blow up the current system to make medicines more affordable. Instead, policymakers should pursue practical policy solutions such as sharing negotiated savings with patients at the pharmacy counter, lowering coinsurance in Medicare Part D, increasing transparency on patients’ costs, promoting value-based contracts, among other improvements to the system. These solutions are better alternatives to the far-reaching proposals in Speaker Pelosi’s plan.”


Industry Watch [to 28 Sep 2019]
Selected Announcements
:: Boehringer Ingelheim donates vaccines to help fight rabies
– The company will donate 60,000 vaccine doses over three years to fight rabies in Puerto Rico
– It is part of a global campaign against a disease that claims an estimated 160 lives a day, half of whom are children(1)
– Rabies is present in more than 150 countries or regions(1)
PRNewswire/ Sep 26, 2019, — Boehringer Ingelheim, a global leader in veterinary rabies vaccines, plans to donate 60,000 doses of its IMRAB® rabies vaccine for dogs over the next three years to fight rabies in Puerto Rico.
The company announced the donations to coincide with World Rabies Day as part of its Shots for Good initiative to help eliminate rabies around the world by vaccinating dogs…